Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.1
Industry P/E
--
EV/EBITDA
1.1
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
16,392,300
CFO
€-387.53 Mln
EBITDA
€-427.32 Mln
Net Profit
€-425.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
| -93.6 | -72.7 | -91.5 | -98.9 | -85.5 | -70.6 | -52.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
| -49.6 | -77.5 | -5.2 | 112.4 | -11.9 | 138.1 | -27.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Affimed N.V. - ADR
|
0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 |
| 4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 | |
| 0.9 | 60.1 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 1.4 | |
| 28.6 | 1,772.7 | 0.0 | -163.7 | -- | -60.9 | -- | 4.7 | |
| 1.7 | 159.1 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 2.9 |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for... CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Read more
Interim CEO, Chief Medical Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
Interim CEO, Chief Medical Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
Headquarters
Mannheim
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Affimed NV - ADR is $0.08 (NASDAQ) as of 18-Jun-2025 09:30 EDT. Affimed NV - ADR has given a return of -85.47% in the last 3 years.
Since, TTM earnings of Affimed NV - ADR is negative, P/E ratio is not available.
The P/B ratio of Affimed NV - ADR is 0.06 times as on 18-Jun-2025, a 99 discount to its peers’ median range of 5.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Affimed NV - ADR are Rs 6.75 and Rs 0.07 as of 03-Apr-2026.
Affimed NV - ADR has a market capitalisation of $ 3 Mln as on 18-Jun-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Affimed NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.